Lilly's framing is explicit in the compound's name and its press materials: this is a selective amylin agonist
Its research profile makes it especially relevant in models focused on body-composition pathways, metabolic adaptation, food-intake signaling, satiety-related biology, and next-generation incretin-adjacent research
Its job is to stop bacteria from growing in the solution
Other facts about the use experience come by deduction of the scientific literature on DSIP and other peptides, as well as our extensive interactions with peptide-prescribing physicians: Preparation: If used as an injectable, DSIP ought to come as a dry powder that needs to be reconstituted into a solution
This positive pressure technique makes drawing easier and more accurate
Research-chemical vials sold as cagrilintide or retatrutide are of unverified identity and purity